Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly concerning its lead program aimed at treating a kidney disease called Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Last year, they achieved important milestones, like receiving special designation from the U.S. FDA for their treatment and getting closer to getting accelerated approval for their medication.
They also made advancements in creating the drug, ensuring its effectiveness, and conducting necessary studies.
XRTX submitted paperwork to regulatory bodies and made strides in technology and patents. An independent assessment suggests their treatment could be very successful commercially.
Looking ahead to 2024, they plan to continue their work on clinical trials and regulatory approval, aiming to move closer to making their treatment available to patients.
Full Release:
https://www.xortx.com/news/press-releases/detail/151/xortx-highlights-achievements-of-2023-and-preparation-for